Alpine Immune Sciences, Inc. (ALPN) Stock Analysis
DELISTED 2024
What happened to Alpine Immune Sciences, Inc. (ALPN) stock?
Alpine Immune Sciences, Inc. (ALPN) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- May 2024
- Last recorded price (historical):
- $64.97 (last quote on record before the May 2024 delisting; historical, not a current quote)
Market cap $4.46B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Alpine Immune Sciences, Inc. (ALPN). Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing protein-based immunotherapies. Their pipeline targets cancer, autoimmune/inflammatory disorders, and other diseases through innovative approaches to modulating the immune system.
Last analyzed: Mar 17, 2026Dated analysis: the newest financial statements on file are 31 months old (Mar 1, 2024), so the figures and score below describe that period, not today.
Alpine Immune Sciences, Inc. (ALPN) Healthcare & Pipeline Overview
More about this archive record
Can I still buy ALPN shares?
No. ALPN stopped trading on public markets in May 2024, so the shares are not available through a broker. Anything you see quoted for ALPN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ALPN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Alpine Immune Sciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.